Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Sees Significant Growth in Short Interest

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 214,479 shares, a growth of 184.8% from the February 26th total of 75,311 shares. Based on an average trading volume of 6,222,165 shares, the days-to-cover ratio is currently 0.0 days. Currently, 13.1% of the shares of the company are short sold.

Catheter Precision Stock Down 1.8%

Shares of VTAK traded down $0.02 during mid-day trading on Friday, hitting $1.09. 67,602 shares of the company traded hands, compared to its average volume of 1,144,497. The stock has a 50-day moving average price of $1.67 and a two-hundred day moving average price of $2.07. Catheter Precision has a 1 year low of $1.05 and a 1 year high of $15.68. The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.20.

Hedge Funds Weigh In On Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision at the end of the most recent reporting period. Institutional investors and hedge funds own 20.34% of the company’s stock.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.